Pharma giant acquires fish health company.
MSD Animal Health, a division of Merck & Co, has signed a definitive agreement to acquire Scan Aqua, the operational affiliate of Scanvacc, a company with expertise in fish health and fish welfare, MSD announced in a press release.
The specific terms of the agreement were not disclosed.
The acquisition of Scan Aqua will include its Rx product portfolio with the key products AQUI-S and Finquel. AQUI-S is a sedative for use during treatment, pumping, transportation, and handling of salmon and rainbow trout. Finquel is a widely-used anaesthetic mainly used in fish farming during the vaccination process and any handling events that require the fish to be fully anaesthetized, such as lice counting.
“The Scan Aqua AS acquisition reinforces MSD Animal Health’s commitment to investing in fish health and fish welfare, as well as to offering its customers new solutions. Vaccination is a key pillar of our preventative health solutions and the use of sedatives complements this approach,” said General Manager MSD Animal Health Norway Dafydd Morris.
“We are delighted to work with MSD Animal Health. They are the ideal partner to help realize the full potential of our fish health products in Norway and in other markets,” said Scanvacc CEO Ole Kristian Kaurstad.